These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9569054)

  • 1. FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study.
    Bajetta E; Di Bartolomeo M; Carnaghi C; Buzzoni R; Mariani L; Gebbia V; Comella G; Pinotti G; Ianniello G; Schieppati G; Bochicchio AM; Maiorino L
    Br J Cancer; 1998 Apr; 77(7):1149-54. PubMed ID: 9569054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.
    Ford PA; Arbuck SG; Minniti C; Miller LL; DeMaria D; O'Dwyer PJ
    Eur J Cancer; 1996 Apr; 32A(4):631-5. PubMed ID: 8695266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group.
    Font A; Moyano AJ; Puerto JM; Tres A; Garcia-Giron C; Barneto I; Anton A; Sanchez JJ; Salvador A; Rosell R
    Cancer; 1999 Feb; 85(4):855-63. PubMed ID: 10091762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.
    Walewski J; Romejko-Jarosińska J; Zwoliński J; Falkowski S; Siedlecki P
    Med Oncol; 1996 Dec; 13(4):199-205. PubMed ID: 9152970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
    O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
    Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL; Douillard JY; Rivière A; Quoix E; Lagrange JL; Berthaud P; Bardonnet-Comte M; Polin V; Gautier V; Milleron B; Chomy F; Chomy P; Spaeth D; Le Chevalier T
    J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
    J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group.
    Bajetta E; Di Bartolomeo M; de Braud F; Bozzetti F; Bochicchio AM; Comella P; Fagnani D; Farina G; Ferroni C; Franchi R
    Eur J Cancer; 1994; 30A(5):596-600. PubMed ID: 8080673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
    Yau JC; Neidhart JA; Triozzi P; Verma S; Nemunaitis J; Quick DP; Mayernik DG; Oette DH; Haynes FA; Holcenberg J
    Am J Hematol; 1996 Apr; 51(4):289-95. PubMed ID: 8602629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma.
    Partyka S; Dumas P; Ajani J
    Cancer; 1999 Jun; 85(11):2336-9. PubMed ID: 10357402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
    Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
    Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte-macrophage colony-stimulating factor given before dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).
    Holdsworth MT; Roon R; Ferguson J; Martinez L; Stidley CA; Neidhart JA
    Biotechnol Ther; 1993; 4(3-4):183-95. PubMed ID: 8292969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy with Tegafur. Uracil (UFT), etoposide, adriamycin and cisplatinum (UFT-EAP) for advanced gastric cancer.
    Hayakawa M; Morise K; Chin K; Sugihara M; Morooka Y; Maeda H; Hattori T; Saito H
    Jpn J Clin Oncol; 1994 Oct; 24(5):282-8. PubMed ID: 7967107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoposide, doxorubicin and cisplatin (EAP regimen) in advanced gastric cancer.
    Scarpellini M; Tononi A; Pasquini E; Oliverio G; Fattori PP; Gianni L; Desiderio F; Nicolini M; Ravaioli A
    J Chemother; 1994 Jun; 6(3):211-5. PubMed ID: 7983505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer.
    Bokemeyer C; Schmoll HJ; Metzner B; Beyer J; Illiger HJ; Kneba M; Ostermann H; Kynast B; Räth U; Poliwoda H
    Ann Hematol; 1993 Aug; 67(2):75-9. PubMed ID: 8347733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.
    Fernandez MC; Krailo MD; Gerbing RR; Matthay KK
    Cancer; 2000 Jun; 88(12):2838-44. PubMed ID: 10870069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
    Paccagnella A; Favaretto A; Riccardi A; Danova M; Ghiotto C; Giordano M; Pappagallo G; Comis S; Panozzo M; Chieco-Bianchi L
    Cancer; 1993 Aug; 72(3):697-706. PubMed ID: 8392903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
    Shaffer DW; Smith LS; Burris HA; Clark GM; Eckardt JR; Fields SM; Weiss GR; Rinaldi DA; Bowen KJ; Kuhn JG
    Cancer Res; 1993 Dec; 53(24):5929-33. PubMed ID: 8261405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP; von Pawel J; Gatzemeier U; Woll P; Thatcher N; Koschel G; Clancy L; Verweij J; de Wit R; Pfeifer W; Fennelly J; von Eiff M; Frisch J
    J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.